Oric Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
ORIC$9.23+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(129,468) | $(127,847) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1,220 | 1,107 |
| Stock-based compensation expense | 25,037 | 20,213 |
| Accretion of discount on investments, net | (2,300) | (8,103) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 1,787 | 143 |
| Accounts payable and accrued other liabilities | (7,246) | 1,825 |
| Net cash used in operating activities | (110,970) | (112,662) |
| Cash flows from investing activities: | ||
| Acquisitions of property and equipment | (712) | (1,188) |
| Purchases of investments | (399,819) | (251,920) |
| Maturities of investments | 252,500 | 275,245 |
| Net cash (used in) provided by investing activities | (148,031) | 22,137 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock and pre-funded warrants | 244,369 | 125,000 |
| Issuance costs associated with financings | (2,397) | (168) |
| Proceeds from issuance of common stock under ESPP | 1,313 | 1,084 |
| Proceeds from stock option exercises | 1,979 | 631 |
| Net cash provided by financing activities | 245,264 | 126,547 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (13,737) | 36,022 |
| Cash, cash equivalents and restricted cash at beginning of period | 59,897 | 23,875 |
| Cash, cash equivalents and restricted cash at end of period | $46,160 | $59,897 |
NOTES TO FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.